Navigation Links
'Move to AMITIZA' Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
Date:11/6/2007

Ads Creatively Depict the Predictable Relief Provided by the Only

Commercially Available Prescription Treatment for Chronic Idiopathic

Constipation in Adults

DEERFIELD, Ill., Nov. 6 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. and Sucampo Pharmaceuticals, Inc. today announced the launch of the first direct-to-consumer (DTC) advertising campaign for AMITIZA(R) (lubiprostone), the only commercially available prescription treatment for Chronic Idiopathic Constipation in adults. The "Move to AMITIZA" campaign illustrates that the predictable relief (defined as 57%-63% had a spontaneous bowel movement within 24 hours with AMITIZA vs. 32%-37% with placebo) provided by AMITIZA may allow people living with chronic idiopathic constipation to move throughout their day without letting their condition slow them down.

"This is welcome news for the millions of Americans who live with Chronic Idiopathic Constipation," said Charles Baum, M.D., medical director, Gastroenterology at Takeda. "This condition remains largely under-treated, in part because only about one in four patients with Chronic Idiopathic Constipation ever visit a physician for treatment-either because people are embarrassed to talk about it, or because they may not be aware that prescription treatment options are available."

The ads, targeting women age 40 years and older, will run in various print and broadcast outlets and encourage people with Chronic Idiopathic Constipation to visit their doctor.

"Through our research, we learned that people with chronic constipation feel the condition slows them down," said Aimee Berner, marketing director, Gastroenterology at Takeda. "According to a nationwide survey conducted by Braun Research, 82 percent of women with chronic constipation have taken over- the-counter medications for relief; and nearly 60 percent of these women report that the treatments work only some of the time or not at all
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc. and Sucampo
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
3. Mediatech Moves to Prince William County Innovation Park
4. FDA Removes Partial Hold on TELCYTA Clinical Development
5. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
6. BioSpace and BayBio Launch 11th Edition of Biotech Bay(TM) Hotbed Map Campaign
7. BioSpace, 2008 BIO International Convention and BIOCOM Launch 9th Edition of Biotech Beach Hotbed Map Campaign
8. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
9. Homewatch CareGivers Launches 2007 We Care For Veterans Campaign
10. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
11. Nanowire generates power by harvesting energy from the environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) announced ... for the Riquent(R) Phase 3 ASPEN trial, the ... of the trial is,futile. BioMarin and partner ... unblind the data and evaluate all of the ...
... announced a vibrant new addition today to their dynamic ... Maine, was unanimously elected by the Board to fill ... successful biotechnology professional with 20 years of experience in ... career accomplishments that include establishing and launching successful business ...
... IdeasProject.com, Nokia,s new website, which provides innovative ways to interact with ... , ... San Francisco, CA (PRWEB) February 12, 2009 ... of genetic testing service 23andme, says that as we further our ...
Cached Biology Technology:Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3SenesTech, Inc. Appoints Susan Airhart to Board of Directors 2Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 2Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 3
(Date:5/26/2015)... May 26, 2015 Research ... addition of the "Saudi Arabia Biometric Systems ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric ... is projected to grow at over 22% ... is attributed to the surging demand for better ...
(Date:5/25/2015)...  Australia,s market for wearable technologies is considered to ... advent of several trials and prototypes. The release of ... to ignite interest in wearables as well as accelerate ... . This in turn will spur greater innovation from ... amongst vendors and distributors. Photo - ...
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... (August 28, 2013) In the United States there are ... undiagnosed because for some athletes, the fear of being benched ... no objective test available to accurately diagnose concussions on the ... set out to change that. , A team led ...
... over time and die. In many organs, like the small ... function by replacing old cells with new ones. Learning ... understand exactly how our organs are built, and why some ... New work from Carnegie,s Alexis Marianes and Allan Spradling used ...
... taller people also tend to be slightly smarter is due ... both traits and taller people are more likely than average ... study led by the University of Colorado Boulder. ... the connection between being taller and being smarter, both traits ...
Cached Biology News:Combating concussions 2Combating concussions 3Why are some cells more cancer prone? 2CU study relies on twins and their parents to understand height-IQ connection 2CU study relies on twins and their parents to understand height-IQ connection 3
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Biology Products: